Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Erasca Inc (ERAS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Erasca's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.140 -0.010    -0.47%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
2.240
+0.100
+4.673%
19:59:10 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 261,791
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.110 - 2.230
Erasca 2.140 -0.010 -0.47%

Erasca Inc Company Profile

 
Get an in-depth profile of Erasca Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

129

Equity Type

ORD

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Contact Information

Address 3115 Merryfield Row Suite 300
San Diego, 92121
United States
Phone 858 465 6511
Fax -

Top Executives

Name Age Since Title
Pratik S. Multani 57 2018 Independent Director
Valerie Harding-Start 64 2019 Independent Director
James A. Bristol 77 2018 Independent Director
John Lo - 2022 Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board
Alexander Whitman Casdin 56 2018 Independent Director
Julie Hambleton 66 2021 Independent Director
Karen Cichowski - - Scientific Advisory Board Member
Pablo Rodriguez-Viciana - - Scientific Advisory Board Member
Bruce D. Roth - - Member of R&D Advisory Board
Linda Robertson - - Member of R&D Advisory Board
Kevan M. Shokat - - Scientific Advisory Board Member
Jonathan E. Lim 52 2018 Co-Founder, Chairman & CEO
Gregory Cosma - - Member of R&D Advisory Board
David Matthews 81 - Member of R&D Advisory Board
Paul G. Pearson 63 - Member of R&D Advisory Board
James L. Freddo 69 - Member of R&D Advisory Board
Ryan B. Corcoran - - Scientific Advisory Board Member
George Daniel Demetri 67 - Scientific Advisory Board Member
Stephen C. Blacklow - - Scientific Advisory Board Member
Jane Chang - - Member of R&D Advisory Board
Jean I. Liu 56 2022 Independent Director
Michael D. Varney 66 2020 Chairman of Research & Development, Scientific Advisory Board Member and Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ERAS Comments

Write your thoughts about Erasca Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Crim Jamer
Crim Jamer Jan 30, 2024 8:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My pending buy order didn't get filled, 5 cents difference.
Crim Jamer
Crim Jamer Jan 30, 2024 8:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
missed the train
Lyudmila Key
Lyudmila Key Jun 15, 2023 11:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bought for $0.45 The move could be epic.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email